Basal cell carcinoma: from pathophysiology to novel therapeutic approaches
Basal cell carcinoma (BCC) is the most common human cancer worldwide, and is a subtype
of nonmelanoma skin cancer, characterized by a constantly increasing incidence due to an …
of nonmelanoma skin cancer, characterized by a constantly increasing incidence due to an …
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
M Smith, E García-Martínez, MR Pitter… - …, 2018 - Taylor & Francis
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …
Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance
NM Nguyen, J Cho - International Journal of Molecular Sciences, 2022 - mdpi.com
Hedgehog (Hh) signaling is a highly conserved pathway that plays a vital role during
embryonic development. Recently, uncontrolled activation of this pathway has been …
embryonic development. Recently, uncontrolled activation of this pathway has been …
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
Y Xun, H Yang, B Kaminska, H You - Journal of hematology & oncology, 2021 - Springer
Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to
current therapies and invariably recurs. Despite some advancements in anti-glioma …
current therapies and invariably recurs. Despite some advancements in anti-glioma …
[HTML][HTML] Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
A Gonnissen, S Isebaert, K Haustermans - Oncotarget, 2015 - ncbi.nlm.nih.gov
An essential role for Hedgehog (Hh) signaling in human cancer has been established
beyond doubt. At present, targeting Hh signaling has mainly been investigated with SMO …
beyond doubt. At present, targeting Hh signaling has mainly been investigated with SMO …
Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
A Bakshi, SC Chaudhary, M Rana… - Molecular …, 2017 - Wiley Online Library
Basal cell carcinoma (BCC) of the skin is driven by aberrant hedgehog signaling. Thus
blocking this signaling pathway by small molecules such as vismodegib inhibits tumor …
blocking this signaling pathway by small molecules such as vismodegib inhibits tumor …
Imiquimod-Its role in the treatment of cutaneous malignancies
AK Bubna - Indian journal of pharmacology, 2015 - journals.lww.com
Imiquimod is a synthetic imidazoquinolone amine, which has potent immune response
modifier activity, when topically used. This characteristic property of imiquimod has led to its …
modifier activity, when topically used. This characteristic property of imiquimod has led to its …
Targeting GLI factors to inhibit the Hedgehog pathway
Hedgehog (Hh) signaling has emerged in recent years as an attractive target for anticancer
therapy because its aberrant activation is implicated in several cancers. Major progress has …
therapy because its aberrant activation is implicated in several cancers. Major progress has …
Hedgehog/GLI signaling in tumor immunity-new therapeutic opportunities and clinical implications
S Grund-Gröschke, G Stockmaier, F Aberger - Cell Communication and …, 2019 - Springer
Uncontrolled activation of the Hedgehog/Glioma-associated oncogene (HH/GLI) pathway is
a potent oncogenic driver signal promoting numerous cancer hallmarks such as …
a potent oncogenic driver signal promoting numerous cancer hallmarks such as …
[HTML][HTML] Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies
J Lanoue, G Goldenberg - The Journal of clinical and aesthetic …, 2016 - ncbi.nlm.nih.gov
Basal cell carcinoma is the most commonly occurring cancer in the world and overall
incidence is still on the rise. While typically a slow-growing tumor for which metastases is …
incidence is still on the rise. While typically a slow-growing tumor for which metastases is …